Le Lézard
Classified in: Health
Subject: CCA

Neovasc to Host Third Quarter 2017 Conference Call



NASDAQ, TSX: NVCN

VANCOUVER, Nov. 10, 2017 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today announced that it will release its financial results for the third quarter 2017 on Tuesday, November 14, 2017, after markets close. The Company will subsequently hold a conference call that same day at 4:30 pm Eastern Time hosted by Mr. Alexei Marko, Chief Executive Officer, and Mr. Chris Clark, Chief Financial Officer. A question and answer session will follow the corporate update.

Conference Call Details


DATE:

Tuesday, November 14, 2017

TIME:

4:30 pm ET

DIAL-IN NUMBER:

888 390 0605 or 416 764 8609

 

A link to the live audio webcast of the conference call will also be available on the Presentations and Events page of the Investors section of Neovasc's website at www.neovasc.com. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to hear the webcast.  

A recording of the call will be available for 72 hours by calling 888 390 0541 or 416 764 8677 and using passcode 762334#.

About Neovasc Inc. 
Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace.  Its products include the Neovasc Reducertm, for the treatment of refractory angina which is not currently available in the United States and has been available in Europe since 2015 and the Tiaratm, for the transcatheter treatment of mitral valve disease, which is currently under investigation in the United States, Canada and Europe. The Company also sells a line of advanced biological tissue products that are used as key components in third-party medical products including transcatheter heart valves. For more information, visit: www.neovasc.com.

SOURCE Neovasc Inc.


These press releases may also interest you

at 03:56
A recent study published in iScience researchers at Kanazawa University describes the role of a molecule, Netrin, in creating borders inside the brain to compartmentalize the functions of the brain.      (Photo:...

at 03:00
Medivir AB  today announces that the transformation to focus the company's internal resources on its clinical development projects has now been completed. Redundancies, mainly within research and administration, are reducing the number of employees...

at 03:00
SynTech Nutrition's vision of total transparency and high-dosage formulations separates it from the rest of the sport supplement industry. "People should know what they are buying and consuming," said Bob Wigman, director...

at 02:13
BioArctic AB (publ) announced today that BioArctic and its partner AbbVie have received U.S. Federal Trade Commission (FTC) clearance to license BioArctic's alpha-synuclein antibody portfolio for Parkinson's disease and other potential indications...

at 02:00
At Today's Inauguration Speech, AI Professor Cees Snoek Gives Preview of First-Ever Body Language Recognition Software During his inauguration address on Video Intelligence at the University of Amsterdam, today, Prof. Cees Snoek gives a preview of...

at 02:00
The bio-pharma industry has entered the new stage of rapid development in recent years with the continuous development of cutting-edge biological technology and the emergence and marketing of new targeted drugs and cell therapies. From the...




News published on 10 november 2017 at 14:56 and distributed by: